Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
复制标题
DOI：
10.1111/bjd.12333
复制
发表时间：
2013-09-01
影响因子：
10.3
通讯作者：
Chang, A. L. S.
中科院分区：
文献类型：
--
作者：
Danial, C.;Lingala, B.;Chang, A. L. S.
转移性基底细胞癌（BCC）是一种罕见但危及生命的疾病。从诊断远处转移到死亡的总生存期（OS）的先前估计约为8-14个月。不过，这些估计数是根据对1984年以前发表的病例报告的分析得出的。目的在单一学术机构评估转移性BCC患者的最新OS。方法回顾性分析1997 - 2011年斯坦福大学医学院活检确诊的远处转移性基底细胞癌病例。Kaplan-Meier分析确定OS和无进展生存期（PFS）。结果连续发现10例远处转移性基底细胞癌。中位OS为7.3年[95%置信区间（CI） 1.6-无穷大]；中位PFS为3.4年（95% CI 1.1-5.2）。结论：我们的研究结果表明，远端转移性BCC患者的OS可能比以前报道的更有利。
Background Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984.Objectives To assess an updated OS in patients with metastatic BCC at a single academic institution.Methods Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS).Results Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7.3 years [95% confidence interval (CI) 1.6-infinity]; median PFS was 3.4 years (95% CI 1.1-5.2).Conclusions Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported.